These are the topics which the National Institute for Health and Care Excellence has been invited to evaluate.

For each proposed evaluation, the table gives the suggested remit, the dates of the consultation on that remit, an e-mail address to send any enquiries to regarding the proposed appraisal, and links to any documents being consulted on in addition to the suggested remit.

 

 

Inotersen for treating hereditary transthyretin-related amyloidosis

Suggested remit

To evaluate the benefits and costs of inotersen within its licensed indication for treating hereditary transthyretin-related amyloidosis for national commissioning by NHS England.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

22 November 2017 – 20 December 2017

 

Batch

58

 

ID number

1242

 

Scoping workshop

Thursday 18 January 2018 – London (AM)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Patisiran for treating hereditary transthyretin-related amyloidosis

Suggested remit

To evaluate the benefits and costs of patisiran within its licensed indication for treating hereditary transthyretin-related amyloidosis for national commissioning by NHS England.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

22 November 2017 – 20 December 2017

 

Batch

58

 

ID number

1279

 

Scoping workshop

Thursday 18 January 2018 – London (AM)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

Volanesorsen for treating familial chylomicronaemia syndrome

Suggested remit

To evaluate the benefits and costs of volanesorsen within its licensed indication for treating adults with familial chylomicronaemia syndrome for national commissioning by NHS England.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

22 November 2017 – 20 December 2017

 

Batch

58

 

ID number

1326

 

Scoping workshop

Thursday 18 January 2018 – London (PM)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top

 

KRN23 for treatment of X- linked hypophosphataemia

Suggested remit

To evaluate the benefits and costs of KRN23 within its licensed indication for treating hypophosphataemia for national commissioning by NHS England.

 

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

16 May – 14 June 2017

 

Batch

55

 

ID number

1151

 

Scoping workshop

Tuesday 4 July 2017 (morning) in (London)

Please send enquiries to: michelle.adhemar@nice.org.uk

 

Consultation documents

 

Back to top